March 4 (Reuters) - Cosmetic drugmaker Evolus ( EOLS )

reported a fourth-quarter profit versus a year-ago loss on

Tuesday, on strong demand for its wrinkle treatment Jeuveau

which competes with Botox.

WHY IT'S IMPORTANT

The company has been targeting a younger demographic

compared to other companies such as Revance and AbbVie ( ABBV ),

among others, which typically focus on people in their 40s.

In February, the U.S. FDA approved Evolus' ( EOLS ) two new dermal

fillers - Evolysse Form and Evolysse Smooth - which are expected

to contribute 8%-10% to its total revenue for 2025.

KEY QUOTE

"We are prepared to launch Evolysse in the second quarter

and will be making significant investments in medical education

and sampling to support our customers and drive adoption," said

CEO David Moatazedi.

BY THE NUMBERS

Evolus ( EOLS ) reported an adjusted income of $6.7 million in the

fourth quarter, compared with a year-ago loss of $3.7 million.

The company sees 2025 revenue between $345 million and $355

million, compared with Wall Street estimates of $351.3 million

according to data compiled by LSEG.

The company projects its annual net revenue can reach at

least $700 million by 2028.